secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009312
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q1 net loss $11.8M; CAHmelia-203 25% enrolled; debt facility amended
--------------------------------------------------------------------------------

- Net loss $11.8M in Q1 2022 vs $9.9M in Q1 2021; cash and investments $108.9M as of March 31, 2022.
- CAHmelia-203 adult classic CAH study reached 25% enrollment; topline data on track for 2H 2023.
- Amended SVB debt facility provides up to $10M credit line in 2022; interest rate cut 50-250 bps.
- Appointed Libbie Mansell, Ph.D., as Chief Regulatory and Quality Officer in April 2022.
- Tildacerfont patent portfolio expanded with two new U.S. method-of-use patents expiring 2038.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017022009312/0000950170-22-009312-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017022009312/sprb-20220511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009312

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer